ReShape Lifesciences reported Q2 2024 revenue of $1.97 million, a year-over-year decline of approximately 12.8%, with six-month revenue of $3.9 million. The quarter featured meaningful cost discipline, delivering roughly 45% lower operating expenses in H1 2024 versus the prior year, and a gross margin expansion to about 58% for Q2 2024 (59% for the six-month period). Despite the top-line weakness driven by GLP-1 adoption pressures, gross profit durability improved due to overhead reductions, notably payroll cuts. Net interest and other income were minimal, and the company remained EBITDA negative (approx. -$2.05 million for Q2) with a net loss of about -$1.60 million for the quarter (EPS of -$3.67). Management underscored a strategic pivot toward commercialization readiness for LAP-Band 2.0 FLEX, ongoing cost reductions, and meaningful corporate actions designed to de-risk balance sheet and unlock long-term value through a Vyome merger and Asset Purchase with Biorad.
Key near-term catalysts include: (1) the limited market release of LAP-Band 2.0 FLEX nearing completion with positive surgeon feedback; (2) the Vyome merger and concurrent asset sale to Biorad to monetize non-core assets and reduce cash burn; (3) a private placement of at least $7.3 million to support the combined entity’s value-driving initiatives; (4) a disciplined, debt-free capital structure that provides optionality to self-fund through mid-2025 and beyond. The company notes that the absolute revenue base remains small while cost controls have materially enhanced gross margin, setting a constructive foundation for a potential margin-advantaged growth path if market acceptance of the LAP-Band 2.0 FLEX accelerates.
Overall Investment Thesis: The stock trades at elevated multiples on a small revenue base (TTM P/S around 63.9x and P/B around 41.3x), reflecting investors’ anticipation of strategic value from the LAP-Band program and the Vyome partnership. The upside hinges on (i) successful scaling of LAP-Band 2.0 FLEX, (ii) execution of the Vyome merger and the asset sale to Biorad, and (iii) sustained cost discipline enabling cash flow generation as GLP-1 headwinds ease. Downside risks include continued GLP-1–driven demand erosion, execution risk in the limited market rollout, and integration risks surrounding the Vyome transaction.